Ensign Peak Advisors
IONS icon

Ensign Peak Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

Ensign Peak Advisors’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$407K Hold
9,120
– – ﹤0.01% 994
2026
Q2 		$723K Sell
9,120
-36,884
-80% -$2.78M ﹤0.01% 895
2026
Q1 		$3.45M Sell
46,004
-7,660
-14% -$605K 0.01% 607
2025
Q4 		$4.25M Buy
53,664
+26,069
+94% +$1.96M 0.01% 551
2025
Q3 		$1.81M Sell
27,595
-25,725
-48% -$1.26M ﹤0.01% 830
2025
Q2 		$2.11M Sell
53,320
-1,780
-3% -$58.3K ﹤0.01% 880
2025
Q1 		$1.66M Buy
55,100
+1,780
+3% +$58.3K ﹤0.01% 988
2024
Q4 		$1.86M Sell
53,320
-16,560
-24% -$619K ﹤0.01% 969
2024
Q3 		$2.8M Buy
69,880
+1,610
+2% +$74.9K ﹤0.01% 813
2024
Q2 		$3.25M Buy
68,270
+14,950
+28% +$613K 0.01% 750
2024
Q1 		$2.31M Buy
53,320
+7,010
+15% +$334K ﹤0.01% 866
2023
Q4 		$2.34M Hold
46,310
– – ﹤0.01% 849
2023
Q3 		$2.1M Hold
46,310
– – ﹤0.01% 826
2023
Q2 		$1.9M Hold
46,310
– – ﹤0.01% 899
2023
Q1 		$1.66M Sell
46,310
-8,581
-16% -$322K ﹤0.01% 923
2022
Q4 		$2.07M Buy
54,891
+22,576
+70% +$950K ﹤0.01% 798
2022
Q3 		$1.43M Buy
32,315
+7,445
+30% +$314K ﹤0.01% 911
2022
Q2 		$921K Hold
24,870
– – ﹤0.01% 1151
2022
Q1 		$921K Sell
24,870
-3,460
-12% -$113K ﹤0.01% 1254
2021
Q4 		$862K Buy
+28,330
New +$892K ﹤0.01% 1366
2021
Q1 		– Sell
-4,882
Closed -$276K – 1858
2020
Q4 		$276K Sell
4,882
-5,198
-52% -$259K ﹤0.01% 1687
2020
Q3 		$478K Buy
+10,080
New +$560K ﹤0.01% 1538
2020
Q1 		– Sell
-5,574
Closed -$337K – 1660
2019
Q4 		$337K Buy
+5,574
New +$332K ﹤0.01% 1577

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Tweedy, Browne Co
Tweedy, Browne Co Stamford, Connecticut $1.23B AUM 16.54% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
GW&K Investment Management
GW&K Investment Management Boston, Massachusetts $11.8B AUM 29.45% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Ensign Peak Advisors's IONS Position: Q3 2026 in Review

Ensign Peak Advisors held its Ionis Pharmaceuticals (IONS) position steady in Q3 2026 at 9,120 shares worth $407K. The position accounts for ﹤0.01% of the portfolio, ranked #994.

Ensign Peak Advisors first reported a position in IONS in Q4 2019 and has held it in 23 quarters since. The position peaked at $4.25M in Q4 2025. 279 funds tracked by Wall St. Rank hold IONS as of Q3 2026.

  • Ensign Peak Advisors held 9,120 shares of Ionis Pharmaceuticals worth $407K as of Q3 2026.
  • Ensign Peak Advisors left its Ionis Pharmaceuticals share count unchanged in Q3 2026.
  • Ionis Pharmaceuticals made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q3 2026, its #994 holding.
  • Ensign Peak Advisors first reported a position in Ionis Pharmaceuticals in Q4 2019 and has held it in 23 quarters since.
  • Ensign Peak Advisors's Ionis Pharmaceuticals position peaked at $4.25M in Q4 2025.
  • 279 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2026.

Based on Ensign Peak Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.